Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Merging index levels with sentiment indicators can enhance conviction and risk controls. This piece provides actionable tips.
21,956 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Investors confront a triple threat as rating concerns, tariff fights, and Middle East risk collide, putting Indonesia...
Horizon (HRZN) investors want clarity on Q3 2025 results and what comes next. This article breaks down horizon (hrzn)...
When Berkshire Hathaway keeps a stake in a company for decades, you want to listen. american express just showed why ...
As XRP hovers in the low-dollar range, investors ask how many tokens would be needed to reach $1 million. The answer ...
Rising internal strife and political pressure push the FDA toward leadership change, with markets watching how the ag...
A surprisingly strong first quarter has some investors asking if Stellantis can shake off years of underperformance. ...
Optex Systems faces a pivotal Q2 2026, balancing defense demand with supply chain shifts. This analysis breaks down t...
Bitcoin fell to a two-week low as leveraged bets were wiped out and risk appetite faded amid geopolitical tensions an...
Pinterest stock is slipping mid-session, dropping around 6% to near $18.75 as peers like Meta and Snap show lighter d...
Take-Two is set to report Q4 results after market close, with GTA VI's looming launch shaping investor sentiment. Gui...
Archer Aviation is racing toward FAA certification, but does that milestone alone justify buying its stock? This guid...